International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (2014-2020), Month: October 2016 - March 2017, Available at: www.researchpublish.com

A Comprehensive Review of Hepatitis B Virus Infection; Pathogenesis, and Management

[1]Hisham Hussain H. Alawaji, [2]Saad Khalil Abuhasbu, [3]Fahad Naif Almarwani, [4]Ali Hussain Alfahal, [5]Ahmed Abdulaziz Almuhamdi, [6]Abdulrahman Samir Khateiri, [7]Atheer Ali Maghram Almoria, [8]Sumayyah Rudda Altalhi, [9]Omaima Tawfiq Al-Omani, [10]Hassan Salman Al Khalaf, [11]Banan Matuq Aloufi, [12]Faisal Mohammed Al-Atawi, [13]Ahmed Daif Allah Hamad Alharbi, [14]Omar Mobarak Almotairi

Abstract: **The main goal of this study was to discuss the pathogenesis and treatment options of hepatitis B virus infection (HBV). We conducted a comprehensive electronic databases of biological and health sciences including MEDLINE (PubMed), Scopus, EMBASE, Embase, Ovid, Google Scholar, and Scientific Information Database (SID). The main keywords used in search for studies included in this review included: "Hepatitis B", "HBV", "Pathogenesis", "Treatment". Search was restricted to English language published until January, 2017. The loved one invisibility of HBV to the innate sensing machinery of the cells probably reflects its duplication method with the replicating viral genome being protected within viral capsid particles in the cytoplasm. The monitoring of dually infected patients also differs from that of HBV-mono-infected patients. With regard to the effect of HIV on HBV, essential modifications occurred with the introduction and also extensive use of effective antiretroviral therapy.**

Keywords: **Hepatitis B Virus Infection (HBV), pathogenesis.**

1. INTRODUCTION

Viral liver disease is a necroinflammatory liver disease of variable seriousness. Persistent infection by HBV is frequently connected with chronic liver disease that could bring about the development of cirrhosis and hepatocellular carcinoma (HCC). It is approximated that greater than 2 billion of the world's population have actually experienced the hepatitis B virus (HBV) infection during their lifetime, as well as there are roughly 350 million patients with chronic liver disease B (CHB) [(1,2)].

Several research studies recommend that HBV is not straight cytopathic for the contaminated hepatocyte [(3,4)]. During the very early stage of HBV infection in primates (i.e., before virus-specific T cells get in the liver), 100% of the hepatocytes may be infected without histological or biochemical evidence of liver disease [(5,6)]. Moreover, when mobile immune feedbacks are deficient or pharmacologically suppressed, HBV can replicate at high degrees in the liver of patients as well as in immunologically forgiving HBV transgenic mice [(4)] in the lack of cytological irregularities or inflammation [(7)].

Viral clearance and also disease pathogenesis are mostly mediated by the adaptive immune reaction in HBV infection [(3)]. For HBV to continue it needs to either not generate an action or it must bewilder, evade or neutralize it. Surprisingly, HBV "averts" the inherent immune feedback by just not generating it, working as a stealth infection in this regard [(8)]. On the other hand, viral persistence is identified by a state of loved one hyporesponsiveness of HBV-specific T cells [(7,9)]. Several viral proteins have actually been revealed to regulate the adaptive immune reaction to HBV recommending that HBV might utilize active evasion strategies targeting the adaptive immune feedback [(6,7,9)]. It has actually been shown that antiviral therapy can conquer CD8+ T cell hyporesponsiveness in chronic HBV infection, recommending that the T cells are present in these topics but suppressed [(10)]. Significantly, a recent study recommends induction of an effective HBV

specific CD8+ T cell response is dependent on early CD4+ T cell priming which could be managed by the size of the viral inoculum [(11)].

The main goal of this study was to discuss the pathogenesis and treatment options of hepatitis B virus infection (HBV).

2. METHODOLOGY

We conducted a comprehensive electronic databases of biological and health sciences including MEDLINE (PubMed), Scopus, EMBASE, Embase, Ovid, Google Scholar, and Scientific Information Database (SID). The main keywords used in search for studies included in this review included: “Hepatitis B”, “HBV”, “Pathogenesis”, “Treatment”. Search was restricted to English language published until January, 2017.

3. RESULTS

Liver disease B virus-- certain immune actions and also necroinflammation (**Figure1**). Because the pathogenesis of HBV-induced liver disease is figured out to a big extent by the stability between the host as well as the infection, initiating ART (with activity versus both HBV and HIV) early in the HIV disease process could positively affect the training course of HBV. ART hastens the reconstruction of both adaptive as well as innate anti-HBV immune feedbacks. For example, the number and also feature of HBV-specific CD4þ as well as CD8þ cells in coinfected patients improved on the initiation of ART [(12)]. ART leads to renovations in the mobile immune action, serologic proof of resolution of the infection, as shown by HBsAg seroconversion, is an infrequent occasion that took place in only 1 of 24 patients in a possible research study [(13)]. In HBV, the immune reaction routed against virally infected hepatocytes results in necrosis as well as transaminase elevation. Since alanine aminotransferase (ALT) degrees correlate, a minimum of somewhat, with the level of necroinflammation, ALT can be a surrogate pen. In two researches, histologic activity and also serial ALT measurements did not differ comparing HBV-monoinfected and HBV/HIV-coinfected patients [(14,15)]. In HBV/ HIV-coinfected patients, however, ALT degrees have been reported to be reduced in patients that have low CD4 cell counts. Fibrogenesis. The impact of HIV on fibrogenesis has been debatable, with some research studies suggesting accelerated fibrogenesis [(16)], as well as others suggesting the converse. Earlier studies that did not report sped up fibrogenesis in HBV/HIV-coinfected patients might have consisted of patients who had much more extensive immunosuppression compared to those included in more modern researches. Confounding factors such as concomitant alcohol usage, distinctions in HBV genotypes, and distinctions in the number of HBeAg-negative topics additionally may have been factors for the lack of an organization between coinfection and also accelerated fibrogenesis [(17)]. In even more current studies, immunosuppression has actually been related to the advancement of cirrhosis: coinfected patients with fewer compared to 200 CD4þ cells/mm3 were significantly more probable to be cirrhotic than those with greater CD4þ cell counts [(18)]. In addition, hepatic decompensation is sped up among coinfected cirrhotic patients in comparison with their monoinfected counterparts [(17)]. An additional factor that affects the progression of fibrosis is HBV genotype. As in HBV-monoinfected patients, HBV genotype G had the best influence on fibrosis development, independent of body mass index, alcohol consumption, gender, or using ART, in HBV/HIV-coinfected patients [(18)].



Figure1: intra-nuclear viral processing produces covalently closed circular DNA

- **Mechanisms of HBV Clearance & Persistence:**

It is commonly believed that the CTL feedback clears viral infections by eliminating infected cells. CTL killing is an inefficient process, nevertheless, requiring direct physical call between the CTLs as well as the contaminated cells. Therefore, it might not be possible for CTLs to kill all HBV contaminated cells if the CTLs are substantially outnumbered as happens during HBV infections in which as several as 1011 hepatocytes can be contaminated [19,20]. Thus, although the liver disease in HBV infection is plainly because of the cytopathic task of the CTL feedback, viral clearance may need extra effective CTL features than murder. Essential understandings right into the noncytopathic as well as pathogenetic antiviral features of the CTL reaction have come from research studies in HBV transgenic computer mice that create an acute necroinflammatory liver disease after adoptive transfer of HBsAg details CTL clones [21,22,23]. In that model (**Figure 2**), the CTLs swiftly enter the liver and acknowledge viral antigen which sets off 2 occasions: (a) apoptosis of the hepatocytes that are literally engaged by the CTLs, as well as (b) secretion of interferon gamma (IFNγ) which noncytopathically inhibits HBV gene expression and also replication in the remainder of the hepatocytes [23,24] by avoiding the setting up of HBV RNA-containing capsids in the cytoplasm [25] in a proteasome and also kinase-dependent process [26,27]. Throughout this exceptional process, the viral nucleocapsids vanish from the cytoplasm of the hepatocytes [23] as well as the viral RNAs are destabilized by a SSB/La-dependent mechanism in the center [27,28], yet the hepatocytes continue to be perfectly healthy and balanced [24]. Antibody blocking and ko experiments in the HBV transgenic mouse version further demonstrated that the antiviral and also cytopathic features of CTLs are completely independent of each other [23]. These outcomes recommend that a strong intrahepatic CTL reaction to HBV can suppress viral gene expression and duplication noncytopathically.



Figure 2: Noncytopathic clearance of HBV from the hepatocyte by T cell- derived cytokines.

- **Hepatocarcinogenesis During HBV Infection:**

Multifactorial systems contribute to the growth of hepatocellular carcinoma (HCC) in chronic HBV infection. Both viral and also host factors consisting of hereditary modifications caused by viral DNA integration, expression of oncogenic viral healthy proteins and chronic immune-mediated liver disease (**Figure 3**) have been implicated as contributing factors [3,30].



Figure 3: The chronic injury → HCC hypothesis.

- **Treatment options of HVB:**

Chemotherapy treatment approach:

HBVr is an usual trouble in patients with CHB and even recuperated patients that are under radiation treatment. Several chemotherapeutic agents are connected with HBVr, including anthracyclines, glucocorticoids, as well as anti-CD20 representatives. The rate of reported HBVr during or after the cessation of cancer radiation treatment differs widely and also highly relies on the underlying disease as well as the therapy regimens. For instance, the occurrence of HBVr in patients with breast cancer that were under radiation treatment without treatments, was reported to range from 20% to 41% [31,32]. These prices considerably reduced using the employment of prophylaxis. Lately, Yang et al. [33] assessed colon or gastric cancer patients with positive HBsAg undergoing chemotherapy. The price of reactivation was reported to be 14.6% (6 from 35). In an evaluation, the rates of HBVr in chronic providers with hepatocellular carcinoma (HCC) undergoing chemotherapy were reported to range from 4% to 67% (34). There are a number of case records of HBVr in patients with chronic myeloid leukemia under chemotherapy [35].

Managment of Autoimmune Diseases can improve the treatment approach of HBV

One of the most reliable therapy in a number of autoimmune diseases is corticosteroids, which are extensively utilized in the therapy of these diseases as well as are related to HBVr. It has been revealed that enhancing the dose of corticosteroids could elevate the risk of infections [36]. The risk of HBVr can significantly increase in patients who got prednisone at high doses (≥ 20 mg/day for a minimum of 4 weeks). Along with corticosteroids, TNF-α inhibitors likewise resulted in the look of resurgence indications [37,38]. In TNF-α targeted treatment, 39% and 5% awakening in HBsAg service providers as well as favorable anti-HBc patients, specifically, were reported. The newly arised therapy, rituximab, which targets B cells, is widely used in radiation treatment in addition to in different autoimmune disease therapies. This treatment is considered to be a most major risk factor of HBVr in autoimmune diseases. A number of studies have actually reported the awakening of HBV as a result of rituximab administration in RA patients [39,40]. Unlike numerous various other immunosuppressants, HBVr because of rituximab administration may occur after 6 months (up to 12 months). This could be explained by the delay in immune reconstitution in these instances. Therefore, along with prompt initiation of antiviral therapy, prophylactic antiviral treatment for at the very least 12 months was suggested after rituximab administration, in various researches [41,42].

4. CONCLUSION

The loved one invisibility of HBV to the innate sensing machinery of the cells probably reflects its duplication method with the replicating viral genome being protected within viral capsid particles in the cytoplasm. On the other hand, HBV can be controlled when correctly turned on HBV-specific CD8+ T cells enter the liver, recognize antigen, kill contaminated cells, and produce IFNγ which triggers a broad-based cascade that intensifies the inflammatory process and has noncytopathic antiviral activity against HBV. Nonetheless, establishment of an efficient flexible antiviral immune response depends on CD4+ T cells and also their priming early in infection probably activated by the subviral antigens existing in the inoculum rather than by the infectious virions. Failing to trigger early CD4+ T cell actions, as occurs in low dosage infections, generates functionally damaged CD8+ T cell responses leading to the establishment of consistent infection. The monitoring of dually infected patients also differs from that of HBV-mono-infected patients. With regard to the effect of HIV on HBV, essential modifications occurred with the introduction and also extensive use of effective antiretroviral therapy (ART).

REFERENCES

[1] Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.

[2] Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70(4):553–61.

[3] Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23–61.

[4] Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol. 1995;69:6158–69.

[5] Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825–9.

[6] Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77:68–76.

[7] Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29–60.

[8] Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004;101:6669–74.

[9] Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med. 1993;177:751–62.

[10] Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med. 1991;174:1565–70.

[11] Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol. 1993;150:4659–71.

[12] Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV infected patient on protease inhibitor. Lancet 1997;349(9057):995–6.

[13] Piroth L, Grappin M, Buisson M, et al. Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23(4):356–7.

[14] Bonacini M, Govindarajan S, Redeker AG. Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol 1991;86(5):570–3.

[15] Housset C, Pol S, Carnot F, et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992;15(4):578–83.

[16] Soriano V, Miro JM, Garcia-Samaniego J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11(1):2–17.

[17] Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006;44(Suppl 1):S65–70.

[18] Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123(6):1812–22.

[19] Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825–9.

[20] Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77:68–76.

[21] Ando K, Guidotti LG, Wirth S, Ishikawa T, Missale G, Moriyama T, et al. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol. 1994;152:3245–53.

[22] Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990;248:361–4.

[23] Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4:25–36.

[24] Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A. 1994;91:3764–8.

[25] Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A. 2005;102:9913–7.

[26] Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol. 2002;76:3570–4.

[27] Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci U S A. 2004;101:1743–7.

[28] Heise T, Guidotti LG, Chisari FV. Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J Virol. 2001;75:6874–83.

[29] Heise T, Guidotti LG, Chisari FV. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol. 1999;73:5767–76.

[30] Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol. 2000;156:1117–32.

[31] Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104(4):559–63.

[32] Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88(3):209–15.

[33] Yang Y, Du Y, Luo WX, Li C, Chen Y, Cheng K, et al. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):783–90.

[34] Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20(24):7675–85.

[35] Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47(1):155–7.

[36] Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis.

2011;70(6):956–60.

[37] Nobili L, Albani L, Gabrielli A, Moroncini G. Reactivation of Hepatitis B Virus Infection Associated with Anti-Tumor Necrosis Factor-a Therapy. J Antivir Antiretrovir. 2014;(6):92–101.

[38] Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31(6):931–6.

[39] Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31(3):403–4.

[40] Salman-Monte TC, Lisbona MP, Garcia-Retortillo M, Maymo J. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin. 2014;10(3):196–7.

[41] Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–9.

[42] Hwang JP, Artz AS, Somerfield MR. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Oncol Pract. 2015;11(4):e487–9.